Medical Imaging

Physicians utilize medical imaging to see inside the body to diagnose and treat patients. This includes computed tomography (CT), magnetic resonance imaging (MRI), X-ray, ultrasound, fluoroscopy, angiography,  and the nuclear imaging modalities of PET and SPECT. 

Thumbnail

Could a tablespoon of peanut butter help diagnose Alzheimer’s?

As neuroimaging technology continues to be researched as a tool for early diagnosis of Alzheimer’s disease, researchers at the University of Florida (UF), Gainesville, have been investigating a much more low-tech alternative requiring only a ruler and a dab of peanut butter.

Thumbnail

First-in-human cannabinoid PET imaging aims for neuro-inflammation

A novel cannabinoid type 2 receptor ligand that binds to microglial and immuno cells could be a hit for neuro-inflammatory imaging, according to a study published in the August 2013 issue of Molecular Imaging and Biology.

MIMICS Emerging Data Suggest Patency Protective Effect

Data presented here yesterday during the Late Breaking Clinical Trials session at VIVA13 show that a stent with unique three dimensional helical geometry, BioMimics 3D™, developed by Veryan Medical Ltd., (Horsham, UK) has demonstrated safety and promising clinical performance at twelve months in the treatment of patients with peripheral arterial disease (PAD) undergoing femoropopliteal artery intervention. 

FDA grants Roche’s Perjeta accelerated approval for use before surgery in people with HER2-positive early stage breast cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (U.S.) Food and Drug Administration (FDA) granted accelerated approval of a Perjeta (pertuzumab) regimen for neoadjuvant treatment (use before surgery) in people with high-risk, HER2-positive early stage breast cancer. This approval is based primarily on data from a Phase II study showing that nearly 40 percent of people receiving the combination of Perjeta, Herceptin (trastuzumab) and docetaxel chemotherapy had no evidence of tumour tissue detectable at the time of surgery (known as a pathological complete response, or pCR). The Perjeta regimen is the first neoadjuvant breast cancer treatment approved by the FDA and also the first to be approved based on pCR data.

ProMedica Breast Care at Toledo Hospital First in Ohio to Adopt VolparaDensity™ Breast Imaging Software to Improve Early Detection of Cancer in Women with Dense Breasts

Matakina International today announced that ProMedica Breast Care on the campus of ProMedica Toledo Hospital became the first in Ohio to offer VolparaDensity™ breast imaging software, designed to help overcome the limitations of mammography to detect cancer in women with dense breasts. Serving Northwest Ohio and Southeast Michigan, the Toledo Hospital Breast Care Center is the region’s premier imaging facility devoted exclusively to patients with breast health concerns and issues and has been named a Breast Imaging Center of Excellence by the American College of Radiology.

Nuclear Medicine and Molecular Imaging Week promotes recent advances

This week, Oct. 6-12, is Nuclear Medicine and Molecular Imaging Week and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the SNMMI Technologist Section (SNMMI-TS) are rallying the medical community to raise public awareness about the industry.

Trimming slice count to cut pediatric CT dose

A limited sequence of axial head CT slices has been demonstrated to reduce radiation exposure by 92 percent compared with standard CT scans in children who need repeated imaging of excessive fluid in the brain, according to a study published online Sept. 20 in the Journal of Neurosurgery.

Merit Medical Acquires Assets of Radial Assist

Merit Medical Systems, Inc. (Nasdaq:MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology, radiology and endoscopy, today announced that it has acquired the assets of Radial Assist, which include the RAD BOARD(R), RAD BOARD(R)XTRA(TM), RAD TRAC(TM), and RAD REST(R) devices.

Around the web

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.